In vitro assessment of combinations of enterovirus inhibitors against enterovirus 71

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 9, 2016, Pages 5357-5367

  Wang, Yizhuo ^a   Li, Guiming ^a,b   Yuan, Shilin ^a   Gao, Qianqian ^a   Lan, Ke ^a   Altmeyer, Ralf ^c   Zou, Gang ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b SHANGHAI UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; FAVIPIRAVIR; ITRACONAZOLE; PROTEIN VP1; RUPINTRIVIR; SURAMIN; 2 PYRROLIDONE DERIVATIVE; 5-IODO-3-((3,5-DIBROMO-4-HYDROXYPHENYL)METHYLENE)-2-INDOLINONE; AMIDE; ANTIVIRUS AGENT; DRUG COMBINATION; INDOLE DERIVATIVE; ISOXAZOLE DERIVATIVE; PHENOL DERIVATIVE; PROTEIN BINDING; PYRAZINE DERIVATIVE; VIRAL PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CYTOPATHOGENIC EFFECT; CYTOTOXICITY ASSAY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; REVERSE ENGINEERING; RHABDOMYOSARCOMA CELL LINE; VERO CELL LINE; VIRUS ATTACHMENT; VIRUS MUTATION; VIRUS REPLICATION; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHLOROCEBUS AETHIOPS; DRUG COMBINATION; DRUG EFFECTS; ENTEROVIRUS A; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MOLECULAR DOCKING; MUTATION; MYOBLAST; PROTEIN DOMAIN; PROTEIN SECONDARY STRUCTURE; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; TUMOR CELL LINE; VIROLOGY;

AMIDES; AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; BINDING SITES; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; ENTEROVIRUS A, HUMAN; HUMANS; INDOLES; ISOXAZOLES; ITRACONAZOLE; MOLECULAR DOCKING SIMULATION; MUTATION; MYOBLASTS; PHENOLS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STRUCTURE, SECONDARY; PYRAZINES; PYRROLIDINONES; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SURAMIN; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84983535187     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01073-16     Document Type: Article

References (51)

1. Chang LY, Lin TY, Hsu KH, Huang YC, Lin KL, Hsueh C, Shih SR, Ning HC, Hwang MS, Wang HS, Lee CY. 1999. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 354:1682-1686. http://dx.doi.org/10.1016/S0140-6736(99)04434-7.
2. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. 2010. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 9:1097-1105. http://dx.doi.org/10.1016/S1474-4422(10)70209-X.
3. Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, Chang Z, Liu F, Fang VJ, Zheng Y, Cowling BJ, Varma JK, Farrar JJ, Leung GM, Yu H. 2014. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis 14:308-318. http://dx.doi.org/10.1016/S1473-3099(13)70342-6.
4. McMinn P, Stratov I, Nagarajan L, Davis S. 2001. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 32:236-242. http://dx.doi.org/10.1086/318454.
5. Zhang Q, Macdonald NE, Smith JC, Cai K, Yu H, Li H, Lei C. 2014. Severe enterovirus type 71 nervous system infections in children in the Shanghai region of China: clinical manifestations and implications for prevention and care. Pediatr Infect Dis J 33:482-487. http://dx.doi.org/10.1097/INF.0000000000000194.
6. Shimizu H, Nakashima K. 2014. Surveillance of hand, foot, and mouth disease for a vaccine. Lancet Infect Dis 14:262-263. http://dx.doi.org/10.1016/S1473-3099(13)70330-X.
7. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR. 1999. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341:929-935.
8. Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. 2003. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 9:78-85. http://dx.doi.org/10.3201/eid1301.020112.
9. Tu PV, Thao NT, Perera D, Huu TK, Tien NT, Thuong TC, How OM, Cardosa MJ, McMinn PC. 2007. Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis 13:1733-1741. http://dx.doi.org/10.3201/eid1311.070632.
10. Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, Mao N, Xu S, Zhu S, Cui A, Yan D, Li Q, Dong X, Zhang J, Zhao Y, Wan J, Feng Z, Sun J, Wang S, Li D, Xu W. 2010. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J 7:94. http://dx.doi.org/10.1186/1743-422X-7-94.
11. Seiff A. 2012. Cambodia unravels cause of mystery illness. Lancet 380:206.
12. Ma E, Chan KC, Cheng P, Wong C, Chuang SK. 2010. The enterovirus 71 epidemic in 2008 - public health implications for Hong Kong. Int J Infect Dis 14:e775-e780. http://dx.doi.org/10.1016/j.ijid.2010.02.2265.
13. Wimmer E, Hellen CU, Cao X. 1993. Genetics of poliovirus. Annu Rev Genet 27:353-436. http://dx.doi.org/10.1146/annurev.ge.27.120193.002033.
14. De Palma AM, Vliegen I, De Clercq E, Neyts J. 2008. Selective inhibitors of picornavirus replication. Med Res Rev 28:823-884. http://dx.doi.org/10.1002/med.20125.
15. Abzug MJ. 2014. The enteroviruses: problems in need of treatments. J Infect 68(Suppl 1):S108-S114. http://dx.doi.org/10.1016/j.jinf.2013.09.020.
16. van der Linden L, Wolthers KC, van Kuppeveld FJ. 2015. Replication and inhibitors of enteroviruses and parechoviruses. Viruses 7:4529-4562. http://dx.doi.org/10.3390/v7082832.
17. Tan CW, Lai JK, Sam IC, Chan YF. 2014. Recent developments in antiviral agents against enterovirus 71 infection. J Biomed Sci 21:14. http://dx.doi.org/10.1186/1423-0127-21-14.
18. Wang Y, Qing J, Sun Y, Rao Z. 2014. Suramin inhibits EV71 infection. Antiviral Res 103:1-6. http://dx.doi.org/10.1016/j.antiviral.2013.12.008.
19. Ren P, Zou G, Bailly B, Xu S, Zeng M, Chen X, Sheng L, Zhang Y, Guillon P, Arenzana-Seisdedos F, Buchy P, Li J, von Itzstein M, Li Q, Altmeyer R. 2014. The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection - suramin inhibits EV71 infection in vitro & in vivo. Emerg Microbes Infect 3:e62. http://dx.doi.org/10.1038/emi.2014.60.
20. Tan CW, Poh CL, Sam IC, Chan YF. 2013. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol 87:611-620. http://dx.doi.org/10.1128/JVI.02226-12.
21. Arita M, Wakita T, Shimizu H. 2008. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol 89:2518-2530. http://dx.doi.org/10.1099/vir.0.2008/002915-0.
22. Nishimura Y, McLaughlin NP, Pan J, Goldstein S, Hafenstein S, Shimizu H, Winkler JD, Bergelson JM. 2015. The suramin derivative NF449 interacts with the 5-fold vertex of the enterovirus A71 capsid to prevent virus attachment to PSGL-1 and heparan sulfate. PLoS Pathog 11:e1005184. http://dx.doi.org/10.1371/journal.ppat.1005184.
23. Strating JR, van der Linden L, Albulescu L, Bigay J, Arita M, Delang L, Leyssen P, van der Schaar HM, Lanke KH, Thibaut HJ, Ulferts R, Drin G, Schlinck N, Wubbolts RW, Sever N, Head SA, Liu JO, Beachy PA, De Matteis MA, Shair MD, Olkkonen VM, Neyts J, van Kuppeveld FJ. 2015. Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein. Cell Rep 10:600-615. http://dx.doi.org/10.1016/j.celrep.2014.12.054.
24. Gao Q, Yuan S, Zhang C, Wang Y, Wang Y, He G, Zhang S, Altmeyer R, Zou G. 2015. Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A. Antimicrob Agents Chemother 59:2654-2665. http://dx.doi.org/10.1128/AAC.05108-14.
25. Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. 2011. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J Virol 85:2364-2372. http://dx.doi.org/10.1128/JVI.02249-10.
26. van der Schaar HM, van der Linden L, Lanke KH, Strating JR, Purstinger G, de Vries E, de Haan CA, Neyts J, van Kuppeveld FJ. 2012. Coxsackievirus mutants that can bypass host factor PI4KIIIbeta and the need for high levels of PI4P lipids for replication. Cell Res 22:1576-1592. http://dx.doi.org/10.1038/cr.2012.129.
27. Arita M, Wakita T, Shimizu H. 2009. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J Gen Virol 90:1869-1879. http://dx.doi.org/10.1099/vir.0.012096-0.
28. Binford SL, Maldonado F, Brothers MA, Weady PT, Zalman LS, Meador JW, III, Matthews DA, Patick AK. 2005. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother 49:619-626. http://dx.doi.org/10.1128/AAC.49.2.619-626.2005.
29. Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, DeLisle DM, Worland ST. 1999. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci U S A 96:11000-11007. http://dx.doi.org/10.1073/pnas.96.20.11000.
30. Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovich PS, Zhou R, Prins TJ, Fuhrman SA, Meador JW, Zalman LS, Matthews DA, Worland ST. 1999. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 43:2444-2450.
31. Sun L, Meijer A, Froeyen M, Zhang L, Thibaut HJ, Baggen J, George S, Vernachio J, van Kuppeveld FJ, Leyssen P, Hilgenfeld R, Neyts J, Delang L. 2015. Antiviral activity of broad-spectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68. Antimicrob Agents Chemother 59:7782-7785. http://dx.doi.org/10.1128/AAC.01375-15.
32. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K. 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46:977-981. http://dx.doi.org/10.1128/AAC.46.4.977-981.2002.
33. Julander JG, Smee DF, Morrey JD, Furuta Y. 2009. Effect of T-705 treatment on Western equine encephalitis in a mouse model. Antiviral Res 82:169-171. http://dx.doi.org/10.1016/j.antiviral.2009.02.201.
34. Delang L, Segura Guerrero N, Tas A, Querat G, Pastorino B, Froeyen M, Dallmeier K, Jochmans D, Herdewijn P, Bello F, Snijder EJ, de Lamballerie X, Martina B, Neyts J, van Hemert MJ, Leyssen P. 2014. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 69:2770-2784. http://dx.doi.org/10.1093/jac/dku209.
35. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, Bailey KW, Furuta Y, Sidwell RW. 2007. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 51:3168-3176. http://dx.doi.org/10.1128/AAC.00356-07.
36. Mendenhall M, Russell A, Smee DF, Hall JO, Skirpstunas R, Furuta Y, Gowen BB. 2011. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. PLoS Negl Trop Dis 5:e1342. http://dx.doi.org/10.1371/journal.pntd.0001342.
37. Rocha-Pereira J, Jochmans D, Dallmeier K, Leyssen P, Nascimento MS, Neyts J. 2012. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun 424:777-780. http://dx.doi.org/10.1016/j.bbrc.2012.07.034.
38. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. 2014. Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 104:153-155. http://dx.doi.org/10.1016/j.antiviral.2014.01.012.
39. Julander JG, Shafer K, Smee DF, Morrey JD, Furuta Y. 2009. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother 53:202-209. http://dx.doi.org/10.1128/AAC.01074-08.
40. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49:981-986. http://dx.doi.org/10.1128/AAC.49.3.981-986.2005.
41. Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. 2013. The ambiguous base-pairing and high substrate efficiency of T-705 (ravipiravir) ribofuranosyl 5′-triphosphate towards influenza A virus polymerase. PLoS One 8:e68347. http://dx.doi.org/10.1371/journal.pone.0068347.
42. Yuan S, Li G, Wang Y, Gao Q, Wang Y, Cui R, Altmeyer R, Zou G. 2016. Identification of positively charged residues in enterovirus 71 capsid protein VP1 essential for production of infectious particles. J Virol 90:741-752. http://dx.doi.org/10.1128/JVI.02482-15.
43. Prichard MN, Shipman C, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res 14:181-205. http://dx.doi.org/10.1016/0166-3542(90)90001-N.
44. Chou TC. 2010. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440-446. http://dx.doi.org/10.1158/0008-5472.CAN-09-1947.
45. Wu Y, Lou Z, Miao Y, Yu Y, Dong H, Peng W, Bartlam M, Li X, Rao Z. 2010. Structures of EV71 RNA-dependent RNA polymerase in complex with substrate and analogue provide a drug target against the hand-footand-mouth disease pandemic in China. Protein Cell 1:491-500. http://dx.doi.org/10.1007/s13238-010-0061-7.
46. Hansen JL, Long AM, Schultz SC. 1997. Structure of the RNA-dependent RNA polymerase of poliovirus. Structure 5:1109-1122. http://dx.doi.org/10.1016/S0969-2126(97)00261-X.
47. Kok CC, McMinn PC. 2009. Picornavirus RNA-dependent RNA polymerase. Int J Biochem Cell Biol 41:498-502. http://dx.doi.org/10.1016/j.biocel.2008.03.019.
48. Thibaut HJ, Leyssen P, Puerstinger G, Muigg A, Neyts J, De Palma AM. 2011. Towards the design of combination therapy for the treatment of enterovirus infections. Antiviral Res 90:213-217. http://dx.doi.org/10.1016/j.antiviral.2011.03.187.
49. Hung HC, Wang HC, Shih SR, Teng IF, Tseng CP, Hsu JT. 2011. Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. J Infect Dis 203:1784-1790. http://dx.doi.org/10.1093/infdis/jir174.
50. Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. 2013. Oxysterol-binding protein family I is the target of minor enviroxime-like compounds. J Virol 87:4252-4260. http://dx.doi.org/10.1128/JVI.03546-12.
51. Thompson AA, Peersen OB. 2004. Structural basis for proteolysis-dependent activation of the poliovirus RNA-dependent RNA polymerase. EMBO J 23:3462-3471. http://dx.doi.org/10.1038/sj.emboj.7600357.